The ALO buyout is odd in that KG now has commercial rights to two very similar drugs: Remoxy from PTIE and Embeda from ALO. Both drugs went before the same FDA advisory panel last week (#msg-33561355, #msg-33590952).
I have to assume that KG thinks there’s a fairly high chance that Emebda will get FDA approval and Remoxy won’t; otherwise, I fail to see the impetus for the buyout.
News 
Market Data 
Discover 
